Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Q2 FY27 Unaudited Consolidated Financial Results
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 23 Oct 2026, 05:30 PM IST · BSE ID: b7487afa-f884-4f70-82ef-e8b0ea14bb85
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr. Reddy's released its latest quarterly and half-yearly financial results, reviewed by auditors.
🤖 AI Summary
- Dr. Reddy's Board approved Unaudited Consolidated Financial Results for the quarter and half-year ended September 30, 2026.
- Results were prepared in compliance with IFRS and Indian Accounting Standards (Ind AS).
- Statutory auditors conducted a limited review and issued unmodified reports on the financial results.
- Filing notes Rs. 529 million from Bion & HCLTech in the US and Rs. 976 million from achievement of certain milestones.
- A provision of Rs. 2,230 million for inventory and Rs. 167 million for associated costs was made in Q1 FY27.
🏢 How This Affects the Company
The company recorded Rs. 529 million in licensing income from Bion & HCLTech in the US and Rs. 976 million from milestone achievements. It also discontinued R&D programs for Chimeric Antigen Receptor (CAR) T-therapy.
A provision of Rs. 2,230 million for inventory and Rs. 167 million for associated costs was recorded in the quarter ended June 30, 2026. The company recognized Rs. 1,350 million in impairment and Rs. 198 million in R&D write-downs related to discontinued CAR T-therapy programs in FY26.
Discontinuation of certain R&D programs for Chimeric Antigen Receptor (CAR) T-therapy streamlines current development status and clinical outcomes.
The company considers ongoing geopolitical conflicts in assessing the recoverability of receivables, goodwill, intangible assets, investments, and other assets.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the reported licensing income and provisions, which impact the company's overall financial health.
🔍
Management Signal
Management is focusing on strategic R&D portfolio adjustments and transparently reporting financial provisions and geopolitical risk assessments.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results – observe revenue and profit trends.
Update on geopolitical assessments and their financial impact.
Details on new licensing agreements or R&D initiatives.
MEDIUM RISK
Ongoing geopolitical conflicts introduce uncertainty, affecting asset recoverability and overall financial stability.
💡 Investor Takeaway
Dr. Reddy's Laboratories filed its Unaudited Financial Results for Q2 FY27, with statutory auditors providing unmodified limited review reports. Key items included Rs. 529 million licensing income and a Rs. 2,230 million inventory provision in Q1 FY27.
⚖️ Strengths & Concerns
✅ Positives
- Generated licensing income of Rs. 529 million from Bion & HCLTech in the US market during the quarter ended September 30, 2026.
- Achieved Rs. 976 million through milestone attainments under various license agreements in the current quarter.
⚠️ Concerns
- Made a provision of Rs. 2,230 million for inventory and Rs. 167 million for associated costs in the quarter ended June 30, 2026.
- Recognized Rs. 1,350 million impairment on non-current assets and Rs. 198 million R&D write-downs related to discontinued CAR T-therapy programs in FY26.
📅 Company Track Record
Dr. Reddy's Q1 FY27 profit stood at INR 4,348 million, down 69.15% YoY. For FY26, the profit was INR 42,466 million, and a dividend of INR 8/- was recommended. These current results provide an update on the company's financial performance following prior year and quarter figures.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What financial results did Dr. Reddy's Laboratories approve for Q2 FY27?
Dr. Reddy's Board approved the Unaudited Consolidated and Standalone Financial Results for the quarter and half-year ended September 30, 2026.
What was the licensing income for Dr. Reddy's Laboratories in the quarter ended September 30, 2026?
Licensing income for the quarter ended September 30, 2026, included Rs. 529 million from Bion & HCLTech in the US and Rs. 976 million from achievement of certain milestones.
What provisions did Dr. Reddy's Laboratories make in the quarter ended June 30, 2026?
A provision of Rs. 2,230 million towards inventory and Rs. 167 million towards associated costs was made in the quarter ended June 30, 2026.
What R&D programs did Dr. Reddy's Laboratories discontinue?
Dr. Reddy's Laboratories decided to discontinue certain R&D programs associated with Chimeric Antigen Receptor (CAR) T-therapy portfolio.
What impairment was recognized by Dr. Reddy's Laboratories for FY26?
An impairment of Rs. 1,350 million on non-current assets and R&D write-downs of Rs. 198 million were recognized in FY26 related to discontinued CAR T-therapy programs.
Questions based on this BSE filing only. For information purposes.